Nvidia agrees to $20B licensing deal with AI chip startup Groq, hiring its CEO and expanding inference capabilities. Analysts maintain Outperform ratings as the chipmaker strengthens its AI dominance.
H.C. Wainwright begins coverage of Inhibikase Therapeutics with a Buy rating and $8 target, citing strong prospects for its Phase 3 PAH drug IKT-001.
Biohaven's (BHVN) experimental depression treatment BHV-7000 didn't meet its primary goal in Phase 2 testing, though some patient subgroups showed promising trends.
FDA confirms proteinuria reduction as valid FSGS approval endpoint in Dimerix feedback, boosting confidence in Travere Therapeutics' upcoming Filspari decision.
Samsung, SK Hynix, and Micron raise HBM3E memory chip prices by 20% as demand surges from AI chipmakers, defying typical pre-launch price drops.
Opendoor acquires HomeBuyer.com to streamline mortgage services and boost home flipping operations across the US real estate market.
